Ontology type: schema:ScholarlyArticle
2017-04-25
AUTHORS ABSTRACTOpinion StatementOpioid analgesics are one of the most commonly prescribed drugs for the treatment of pain, but there are many potentially harmful side effects with their prolonged use. In light of the escalating opioid epidemic, there is a drive to search for novel analgesics or potential combination therapies that may reduce the incidence of side effects. Serotonergic compounds are used in the clinic for the treatment of chronic pain. Of these compounds, ligands that act at the 5-HT2a and 5-HT2c receptors may be clinically useful as adjunctive therapies to opioids. The purpose of this review is to describe the preclinical evidence supporting the role of these receptors in pain states and how these receptors interact with opioid analgesics. 5-HT2a receptor antagonists have shown efficacy in the reducing nocifensive, or pain-like withdrawal behaviors or responses, associated with neuropathy and inflammation. In addition, the 5-HT2a receptor may interact on a cellular level with the mu opioid receptor. 5-HT2c agonists are reported to act as antinociceptive agents when administered directly into the spinal cord. 5-HT2c agonists also attenuate behavioral symptoms of opioid dependence, though nothing is known about their interactions with opioid analgesics. In conclusion, although the preclinical literature poses a potentially interesting role for the 5-HT2a/2c receptors in nociception, their interaction with the MOR is unclear and needs further preclinical evaluation. More... »
PAGES210-220
http://scigraph.springernature.com/pub.10.1007/s40501-017-0111-3
DOIhttp://dx.doi.org/10.1007/s40501-017-0111-3
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1085054886
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Pharmacology and Pharmaceutical Sciences",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Pharmacology and Toxicology, Virginia Commonwealth University, 1112 East Clay Street, McGuire Hall, Room 100, P.O. Box 980613, 23298-0613, Richmond, VA, USA",
"id": "http://www.grid.ac/institutes/grid.224260.0",
"name": [
"Department of Pharmacology and Toxicology, Virginia Commonwealth University, 1112 East Clay Street, McGuire Hall, Room 100, P.O. Box 980613, 23298-0613, Richmond, VA, USA"
],
"type": "Organization"
},
"familyName": "Lippold",
"givenName": "Kumiko",
"id": "sg:person.0774125317.19",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774125317.19"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Pharmacology and Toxicology, Virginia Commonwealth University, 1112 East Clay Street, McGuire Hall, Room 100, P.O. Box 980613, 23298-0613, Richmond, VA, USA",
"id": "http://www.grid.ac/institutes/grid.224260.0",
"name": [
"Department of Pharmacology and Toxicology, Virginia Commonwealth University, 1112 East Clay Street, McGuire Hall, Room 100, P.O. Box 980613, 23298-0613, Richmond, VA, USA"
],
"type": "Organization"
},
"familyName": "Dewey",
"givenName": "William",
"id": "sg:person.01316575654.94",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01316575654.94"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1016/s0893-133x(99)00004-4",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1050840834",
"https://doi.org/10.1016/s0893-133x(99)00004-4"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00213-012-2870-2",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1000075998",
"https://doi.org/10.1007/s00213-012-2870-2"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/bf00401407",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1007385943",
"https://doi.org/10.1007/bf00401407"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/npp.2011.303",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1038645859",
"https://doi.org/10.1038/npp.2011.303"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/npp.2016.259",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1001527708",
"https://doi.org/10.1038/npp.2016.259"
],
"type": "CreativeWork"
}
],
"datePublished": "2017-04-25",
"datePublishedReg": "2017-04-25",
"description": "Opinion StatementOpioid analgesics are one of the most commonly prescribed drugs for the treatment of pain, but there are many potentially harmful side effects with their prolonged use. In light of the escalating opioid epidemic, there is a drive to search for novel analgesics or potential combination therapies that may reduce the incidence of side effects. Serotonergic compounds are used in the clinic for the treatment of chronic pain. Of these compounds, ligands that act at the 5-HT2a and 5-HT2c receptors may be clinically useful as adjunctive therapies to opioids. The purpose of this review is to describe the preclinical evidence supporting the role of these receptors in pain states and how these receptors interact with opioid analgesics. 5-HT2a receptor antagonists have shown efficacy in the reducing nocifensive, or pain-like withdrawal behaviors or responses, associated with neuropathy and inflammation. In addition, the 5-HT2a receptor may interact on a cellular level with the mu opioid receptor. 5-HT2c agonists are reported to act as antinociceptive agents when administered directly into the spinal cord. 5-HT2c agonists also attenuate behavioral symptoms of opioid dependence, though nothing is known about their interactions with opioid analgesics. In conclusion, although the preclinical literature poses a potentially interesting role for the 5-HT2a/2c receptors in nociception, their interaction with the MOR is unclear and needs further preclinical evaluation.",
"genre": "article",
"id": "sg:pub.10.1007/s40501-017-0111-3",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1049709",
"issn": [
"2196-3061"
],
"name": "Current Treatment Options in Psychiatry",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "2",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "4"
}
],
"keywords": [
"opioid analgesics",
"preclinical literature",
"side effects",
"treatment of pain",
"mu-opioid receptors",
"potential combination therapy",
"further preclinical evaluation",
"adjunctive therapy",
"pain states",
"opioid antinociception",
"preclinical evidence",
"chronic pain",
"opioid dependence",
"harmful side effects",
"combination therapy",
"receptor antagonist",
"opioid receptors",
"novel analgesics",
"serotonergic compounds",
"opioid epidemic",
"spinal cord",
"antinociceptive agents",
"preclinical evaluation",
"analgesics",
"behavioral symptoms",
"receptors",
"pain",
"nociception",
"therapy",
"agonists",
"cellular level",
"treatment",
"withdrawal behavior",
"neuropathy",
"antinociception",
"opioids",
"inflammation",
"review",
"clinic",
"cord",
"antagonist",
"symptoms",
"incidence",
"drugs",
"efficacy",
"role",
"epidemic",
"conclusion",
"effect",
"agents",
"interesting role",
"response",
"evidence",
"levels",
"literature",
"evaluation",
"MOR",
"use",
"compounds",
"purpose",
"addition",
"interaction",
"state",
"light",
"behavior",
"drive",
"dependence"
],
"name": "The Role of 5-HT2a/2c Receptors in Nociception and Opioid Antinociception: a Review of the Preclinical Literature",
"pagination": "210-220",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1085054886"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s40501-017-0111-3"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s40501-017-0111-3",
"https://app.dimensions.ai/details/publication/pub.1085054886"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T17:06",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_751.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s40501-017-0111-3"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40501-017-0111-3'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40501-017-0111-3'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40501-017-0111-3'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40501-017-0111-3'
This table displays all metadata directly associated to this object as RDF triples.
150 TRIPLES
21 PREDICATES
96 URIs
83 LITERALS
6 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1007/s40501-017-0111-3 | schema:about | anzsrc-for:11 |
2 | ″ | ″ | anzsrc-for:1115 |
3 | ″ | schema:author | N7fe1bf902f4e4469b4a7df735f6b6916 |
4 | ″ | schema:citation | sg:pub.10.1007/bf00401407 |
5 | ″ | ″ | sg:pub.10.1007/s00213-012-2870-2 |
6 | ″ | ″ | sg:pub.10.1016/s0893-133x(99)00004-4 |
7 | ″ | ″ | sg:pub.10.1038/npp.2011.303 |
8 | ″ | ″ | sg:pub.10.1038/npp.2016.259 |
9 | ″ | schema:datePublished | 2017-04-25 |
10 | ″ | schema:datePublishedReg | 2017-04-25 |
11 | ″ | schema:description | Opinion StatementOpioid analgesics are one of the most commonly prescribed drugs for the treatment of pain, but there are many potentially harmful side effects with their prolonged use. In light of the escalating opioid epidemic, there is a drive to search for novel analgesics or potential combination therapies that may reduce the incidence of side effects. Serotonergic compounds are used in the clinic for the treatment of chronic pain. Of these compounds, ligands that act at the 5-HT2a and 5-HT2c receptors may be clinically useful as adjunctive therapies to opioids. The purpose of this review is to describe the preclinical evidence supporting the role of these receptors in pain states and how these receptors interact with opioid analgesics. 5-HT2a receptor antagonists have shown efficacy in the reducing nocifensive, or pain-like withdrawal behaviors or responses, associated with neuropathy and inflammation. In addition, the 5-HT2a receptor may interact on a cellular level with the mu opioid receptor. 5-HT2c agonists are reported to act as antinociceptive agents when administered directly into the spinal cord. 5-HT2c agonists also attenuate behavioral symptoms of opioid dependence, though nothing is known about their interactions with opioid analgesics. In conclusion, although the preclinical literature poses a potentially interesting role for the 5-HT2a/2c receptors in nociception, their interaction with the MOR is unclear and needs further preclinical evaluation. |
12 | ″ | schema:genre | article |
13 | ″ | schema:isAccessibleForFree | false |
14 | ″ | schema:isPartOf | N08f5577403e049a08dff7dbf4244b711 |
15 | ″ | ″ | Nb9080e1891a047aeb4040ea170b4032a |
16 | ″ | ″ | sg:journal.1049709 |
17 | ″ | schema:keywords | MOR |
18 | ″ | ″ | addition |
19 | ″ | ″ | adjunctive therapy |
20 | ″ | ″ | agents |
21 | ″ | ″ | agonists |
22 | ″ | ″ | analgesics |
23 | ″ | ″ | antagonist |
24 | ″ | ″ | antinociception |
25 | ″ | ″ | antinociceptive agents |
26 | ″ | ″ | behavior |
27 | ″ | ″ | behavioral symptoms |
28 | ″ | ″ | cellular level |
29 | ″ | ″ | chronic pain |
30 | ″ | ″ | clinic |
31 | ″ | ″ | combination therapy |
32 | ″ | ″ | compounds |
33 | ″ | ″ | conclusion |
34 | ″ | ″ | cord |
35 | ″ | ″ | dependence |
36 | ″ | ″ | drive |
37 | ″ | ″ | drugs |
38 | ″ | ″ | effect |
39 | ″ | ″ | efficacy |
40 | ″ | ″ | epidemic |
41 | ″ | ″ | evaluation |
42 | ″ | ″ | evidence |
43 | ″ | ″ | further preclinical evaluation |
44 | ″ | ″ | harmful side effects |
45 | ″ | ″ | incidence |
46 | ″ | ″ | inflammation |
47 | ″ | ″ | interaction |
48 | ″ | ″ | interesting role |
49 | ″ | ″ | levels |
50 | ″ | ″ | light |
51 | ″ | ″ | literature |
52 | ″ | ″ | mu-opioid receptors |
53 | ″ | ″ | neuropathy |
54 | ″ | ″ | nociception |
55 | ″ | ″ | novel analgesics |
56 | ″ | ″ | opioid analgesics |
57 | ″ | ″ | opioid antinociception |
58 | ″ | ″ | opioid dependence |
59 | ″ | ″ | opioid epidemic |
60 | ″ | ″ | opioid receptors |
61 | ″ | ″ | opioids |
62 | ″ | ″ | pain |
63 | ″ | ″ | pain states |
64 | ″ | ″ | potential combination therapy |
65 | ″ | ″ | preclinical evaluation |
66 | ″ | ″ | preclinical evidence |
67 | ″ | ″ | preclinical literature |
68 | ″ | ″ | purpose |
69 | ″ | ″ | receptor antagonist |
70 | ″ | ″ | receptors |
71 | ″ | ″ | response |
72 | ″ | ″ | review |
73 | ″ | ″ | role |
74 | ″ | ″ | serotonergic compounds |
75 | ″ | ″ | side effects |
76 | ″ | ″ | spinal cord |
77 | ″ | ″ | state |
78 | ″ | ″ | symptoms |
79 | ″ | ″ | therapy |
80 | ″ | ″ | treatment |
81 | ″ | ″ | treatment of pain |
82 | ″ | ″ | use |
83 | ″ | ″ | withdrawal behavior |
84 | ″ | schema:name | The Role of 5-HT2a/2c Receptors in Nociception and Opioid Antinociception: a Review of the Preclinical Literature |
85 | ″ | schema:pagination | 210-220 |
86 | ″ | schema:productId | N167db6e19a5c4e79a7efad8b419d47d6 |
87 | ″ | ″ | N39c1ec32d1ed4642acfc10625d78a540 |
88 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1085054886 |
89 | ″ | ″ | https://doi.org/10.1007/s40501-017-0111-3 |
90 | ″ | schema:sdDatePublished | 2022-08-04T17:06 |
91 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
92 | ″ | schema:sdPublisher | N68db4734d2c241519db9885ef93cc5e4 |
93 | ″ | schema:url | https://doi.org/10.1007/s40501-017-0111-3 |
94 | ″ | sgo:license | sg:explorer/license/ |
95 | ″ | sgo:sdDataset | articles |
96 | ″ | rdf:type | schema:ScholarlyArticle |
97 | N08f5577403e049a08dff7dbf4244b711 | schema:issueNumber | 2 |
98 | ″ | rdf:type | schema:PublicationIssue |
99 | N167db6e19a5c4e79a7efad8b419d47d6 | schema:name | dimensions_id |
100 | ″ | schema:value | pub.1085054886 |
101 | ″ | rdf:type | schema:PropertyValue |
102 | N210c916b5715493896ac0bf7b5c33b95 | rdf:first | sg:person.01316575654.94 |
103 | ″ | rdf:rest | rdf:nil |
104 | N39c1ec32d1ed4642acfc10625d78a540 | schema:name | doi |
105 | ″ | schema:value | 10.1007/s40501-017-0111-3 |
106 | ″ | rdf:type | schema:PropertyValue |
107 | N68db4734d2c241519db9885ef93cc5e4 | schema:name | Springer Nature - SN SciGraph project |
108 | ″ | rdf:type | schema:Organization |
109 | N7fe1bf902f4e4469b4a7df735f6b6916 | rdf:first | sg:person.0774125317.19 |
110 | ″ | rdf:rest | N210c916b5715493896ac0bf7b5c33b95 |
111 | Nb9080e1891a047aeb4040ea170b4032a | schema:volumeNumber | 4 |
112 | ″ | rdf:type | schema:PublicationVolume |
113 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
114 | ″ | schema:name | Medical and Health Sciences |
115 | ″ | rdf:type | schema:DefinedTerm |
116 | anzsrc-for:1115 | schema:inDefinedTermSet | anzsrc-for: |
117 | ″ | schema:name | Pharmacology and Pharmaceutical Sciences |
118 | ″ | rdf:type | schema:DefinedTerm |
119 | sg:journal.1049709 | schema:issn | 2196-3061 |
120 | ″ | schema:name | Current Treatment Options in Psychiatry |
121 | ″ | schema:publisher | Springer Nature |
122 | ″ | rdf:type | schema:Periodical |
123 | sg:person.01316575654.94 | schema:affiliation | grid-institutes:grid.224260.0 |
124 | ″ | schema:familyName | Dewey |
125 | ″ | schema:givenName | William |
126 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01316575654.94 |
127 | ″ | rdf:type | schema:Person |
128 | sg:person.0774125317.19 | schema:affiliation | grid-institutes:grid.224260.0 |
129 | ″ | schema:familyName | Lippold |
130 | ″ | schema:givenName | Kumiko |
131 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774125317.19 |
132 | ″ | rdf:type | schema:Person |
133 | sg:pub.10.1007/bf00401407 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1007385943 |
134 | ″ | ″ | https://doi.org/10.1007/bf00401407 |
135 | ″ | rdf:type | schema:CreativeWork |
136 | sg:pub.10.1007/s00213-012-2870-2 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1000075998 |
137 | ″ | ″ | https://doi.org/10.1007/s00213-012-2870-2 |
138 | ″ | rdf:type | schema:CreativeWork |
139 | sg:pub.10.1016/s0893-133x(99)00004-4 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1050840834 |
140 | ″ | ″ | https://doi.org/10.1016/s0893-133x(99)00004-4 |
141 | ″ | rdf:type | schema:CreativeWork |
142 | sg:pub.10.1038/npp.2011.303 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1038645859 |
143 | ″ | ″ | https://doi.org/10.1038/npp.2011.303 |
144 | ″ | rdf:type | schema:CreativeWork |
145 | sg:pub.10.1038/npp.2016.259 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1001527708 |
146 | ″ | ″ | https://doi.org/10.1038/npp.2016.259 |
147 | ″ | rdf:type | schema:CreativeWork |
148 | grid-institutes:grid.224260.0 | schema:alternateName | Department of Pharmacology and Toxicology, Virginia Commonwealth University, 1112 East Clay Street, McGuire Hall, Room 100, P.O. Box 980613, 23298-0613, Richmond, VA, USA |
149 | ″ | schema:name | Department of Pharmacology and Toxicology, Virginia Commonwealth University, 1112 East Clay Street, McGuire Hall, Room 100, P.O. Box 980613, 23298-0613, Richmond, VA, USA |
150 | ″ | rdf:type | schema:Organization |